Neurotoxicity of ecstasy (MDMA): An overview
Department of Neurotoxicology, National Center for Toxicological Research/Food and Drug Administration, Jefferson, AR 72079, USA. Current pharmaceutical biotechnology
(Impact Factor: 2.51).
08/2010; 11(5):460-9. DOI: 10.2174/138920110791591490
"Ecstasy" (MDMA) is a powerful hallucinogenic drug which has raised concern worldwide because of its high abuse liability. A plethora of studies have demonstrated that MDMA has the potential to induce neurotoxicity both in human and laboratory animals. Although research on MDMA has been carried out by many different laboratories, the mechanism underlying MDMA induced toxicity has not been fully elucidated. MDMA has the ability to reduce serotonin levels in terminals of axons in the cortex of rats and mice. Recently we have shown that it also has the potential to produce degenerate neurons in discrete areas of the brain such as insular and parietal cortex, thalamus, tenia tecta and bed nucleus of stria terminalis (BST). Acute effects of MDMA can result in a constellation of changes including arrthymias, hypertension, hyperthermia, serotonin (5-HT) syndrome, liver problems, seizures and also long lasting neurocognitive impairments including mood disturbances. In human MDMA abusers, there is evidence for reduction of serotonergic biochemical markers. Several factors may contribute to the MDMA-induced neurotoxicity, especially hyperthermia. Other factors potentially influencing MDMA toxicity include monoamine oxidase metabolism of dopamine and serotonin, nitric oxide generation, glutamate excitotoxicity, serotonin 2A receptor agonism and the formation of MDMA neurotoxic metabolites. In this review we will cover the following topics: pharmacological mechanisms, metabolic pathways and acute effects in laboratory animals, as well as in humans, with special attention on the mechanism and pathology of MDMA induced neurotoxicity.
Available from: Amy K Goodwin
- "Hence, clinically relevant comparisons of the behavioral and pharmacokinetic effects of MDMA must include a consideration of the dose range and dosing schedules used. For example, human studies of the behavioral and pharmacokinetic effects of MDMA have been limited to the lower portion of the abused MDMA dose range [for review, see Parrott (2005)] and this is likely due to the neurotoxic effects of MDMA reported in rodents and nonhuman primates (Sarkar and Schmued, 2010). We sought to follow up on our previous work with oral MDMA in the baboon (Mueller et al., 2011) to characterize the behavioral effects of MDMA across a wide dose range (0.32–7.8 mg/kg) as well as to determine the plasma concentration-over-time profiles of MDMA and its major metabolites in the same subjects. "
[Show abstract] [Hide abstract]
ABSTRACT: (±)-3,4-Methylenedioxymethamphetamine HCl (MDMA, "Ecstasy") is a popular drug of abuse. We aimed to characterize the behavioral effects of intragastric MDMA in a species closely related to humans and to relate behavioral effects to plasma MDMA and metabolite concentrations. Single doses of MDMA (0.32 - 7.8 mg/kg) were administered via an intragastric catheter to adult male baboons (N=4). Effects of MDMA on food-maintained responding were assessed over a 20-h period, while untrained behaviors and fine-motor coordination were characterized every 30 min until 3 h post-administration. Levels of MDMA and metabolites in plasma were measured in the same animals (N=3) following dosing on a separate occasion. MDMA decreased food-maintained responding over the 20-h period, and systematic behavioral observations revealed increased frequency of bruxism as the dose of MDMA was increased. Drug blood level determinations showed no MDMA after the lower doses of MDMA tested (0.32-1.0 mg/kg) and modest levels following higher MDMA doses (3.2-7.8 mg/kg). High levels of 3,4-dihydroxymethamphetamine (HHMA) were detected after all doses of MDMA, suggesting extensive first-pass metabolism of MDMA in the baboon. The present results demonstrate that MDMA administered via an intragastric catheter produced behavioral effects that have also been reported in humans. Similar to humans, blood levels of MDMA following oral administration may not be predictive of the behavioral effects of MDMA. Metabolites, particularly HHMA, may play a significant role in the behavioral effects of MDMA.
Journal of Pharmacology and Experimental Therapeutics 03/2013; 345(3). DOI:10.1124/jpet.113.203729 · 3.97 Impact Factor
Available from: Alvaro Llorente-Berzal
- "Brain serotonin systems have been associated with the rewarding effects of MDMA, and serotonin antagonists block MDMA-induced CPP (Bilsky and Reid, 1991). Moreover, MDMA acts primarily by releasing 5-HT from presynaptic 5-HT terminals (Schmidt et al., 1987), which eventually leads to a persistent loss of brain serotonergic neuron functioning and a reduction in 5-HT and 5-HIAA levels (Battaglia et al., 1987; Sarkar and Schmued, 2010). Previous studies have shown that different protocols of maternal separation can induce alterations in brain serotonergic systems, such as decreased 5-HT levels in the ventral striatum (Kosten et al., 2004), increased hippocampal 5- HT1A and 5-HT1B receptors and cortical 5-HT2 receptors and lower levels of 5-HT1A receptors in the raphe nuclei (Vázquez et al., 2002), and higher SERT levels in the amygdala (Vicentic et al., 2006). "
[Show abstract] [Hide abstract]
ABSTRACT: The early neonatal stage constitutes a sensitive period during which exposure to adverse events can increase the risk of neuropsychiatric disorders. Maternal deprivation (MD) is a model of early life stress that induces long-term behavioural and physiological alterations, including susceptibility to different drugs of abuse. In the present study we have used the conditioned place preference (CPP) paradigm to address the influence of MD on the rewarding effects of 3,4-methylenedioxymetamphetamine (MDMA) in adolescent animals of both sexes. We have previously observed in adolescent rats that MD induces modifications in the serotonergic and endocannabinoid systems, which play a role in the rewarding effects of MDMA. In light of this evidence, we hypothesized that MD would alter the psychobiological consequences of exposure to MDMA. Neonatal Wistar rats underwent MD (24h, on PND9) or were left undisturbed (controls). The animals were conditioned with 2.5mg/kg MDMA during the periadolescent period (PND34-PND43) and were tested in the open-field test at the end of adolescence (PND 60). Animals were sacrificed on PND 68-75 and levels of serotonin (5-HT) and its metabolite 5-hydroxyindole acetic acid were measured in the striatum, hippocampus and cortex, while the expression of hippocampal CB1 cannabinoid receptor (CB1R) and circulating levels of corticosterone and leptin were also measured. Control males showed CPP after administration of MDMA. However, no MDMA-induced CPP was detected in control females or MD males, and MD had no effect on open field activity in any group. A reduction in striatal and cortical 5-HT levels, increased expression of hippocampal CB1R and a marked trend towards higher circulating leptin levels were observed in MDMA-treated MD males. Our results demonstrate for the first time that MD reduces the rewarding effects of MDMA in a sex-dependent manner. We propose that this effect is related, at least in part, with alterations of the serotonergic and cannabinoid systems.
Toxicology 12/2012; 311(1). DOI:10.1016/j.tox.2012.12.003 · 3.62 Impact Factor
Available from: ijnp.oxfordjournals.org
- "Animals treated with repeated doses of MDMA develop lasting reductions in various presynaptic serotonergic neuronal markers including 5-HT, 5-hydroxyindoleacetic acid (5-HIAA, 5-HT's major metabolite), tryptophan hydroxylase (5-HT's rate-limiting biosynthetic enzyme) and membrane 5-HT transporters (SERTs). Accompanying these lasting 5-HT neurochemical deficits are morphological changes that are pathognomonic of 5-HT nerve fibre damage (Callahan et al. 2001 ; Molliver et al. 1990 ; Sarkar & Schmued, 2010). There are also data indicating that humans are susceptible to MDMA-induced 5-HT neural injury. "
[Show abstract] [Hide abstract]
ABSTRACT: Repeated doses of the popular recreational drug methylenedioxymethamphetamine (MDMA, 'Ecstasy') are known to produce neurotoxic effects on brain serotonin (5-HT) neurons but it is widely believed that typical single oral doses of MDMA are free of neurotoxic risk. Experimental and therapeutic trials with MDMA in humans are underway. The mechanisms by which MDMA produces neurotoxic effects are not understood but drug metabolites have been implicated. The aim of the present study was to assess the neurotoxic potential of a range of clinically relevant single oral doses of MDMA in a non-human primate species that metabolizes MDMA in a manner similar to humans, the squirrel monkey. A secondary objective was to explore the relationship between plasma MDMA and metabolite concentrations and lasting serotonergic deficits. Single oral doses of MDMA produced lasting dose-related serotonergic neurochemical deficits in the brains of squirrel monkeys. Notably, even the lowest dose of MDMA tested (5.7 mg/kg, estimated to be equivalent to 1.6 mg/kg in humans) produced significant effects in some brain regions. Plasma levels of MDMA engendered by neurotoxic doses of MDMA were on the order of those found in humans. Serotonergic neurochemical markers were inversely correlated with plasma concentrations of MDMA, but not with those of its major metabolites, 3,4-dihydroxymethamphetamine and 4-hydroxy-3-methoxymethamphetamine. These results suggest that single oral doses of MDMA in the range of those used by humans pose a neurotoxic risk and implicate the parent compound (MDMA), rather than one of its metabolites, in MDMA-induced 5-HT neural injury.
The International Journal of Neuropsychopharmacology 07/2012; 16(04):1-11. DOI:10.1017/S1461145712000582 · 4.01 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.